VivoSim Labs Says It Regained Compliance With Nasdaq $2.5M Stockholders' Equity Rule After $5M Eli Lilly Milestone Payment, $4M Financing; Reports $10.1M Cash On Hand
Share
Why It Matters
VivoSim Labs got back on track with Nasdaq rules by receiving money from a deal with Eli Lilly and raising more cash. When a company fixes a money problem like this, it shows they found a way to stay in the game, though you'd want to watch if they keep growing their real business.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.